No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
AU Stock MarketDetailed Quotes
TYP Tryptamine Therapeutics Ltd
- 0.042
- -0.001-2.33%
20min DelayMarket Closed Jan 3 16:00 AET
53.61MMarket Cap-0.46P/E (Static)
0.043High0.040Low881.95KVolume0.043Open0.043Pre Close36.32KTurnover0.05752wk High0.11%Turnover Ratio1.28BShares0.01752wk Low-0.038EPS TTM33.84MFloat Cap0.057Historical HighLossP/E (Static)805.64MShs Float0.017Historical Low-0.091EPS LYR6.98%Amplitude--Dividend TTM10.50P/B1Lot Size--Div YieldTTM
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Tryptamine Therapeutics Fields Positive Early Results in Phase 2a Irritable Bowel Syndrome Trial
Tryptamine Therapeutics Phase 1b Study Refines Dose of IV Psilocin in Obese Subjects
Tryptamine Therapeutics Doses First Patient in IV-infused Psilocin Phase 1b Study
Tryptamine to Plug $6M Placement Funding Into Acceleration of IV-infused Psilocybin Treatment Trials
Tryptamine Therapeutics A$6 Million Placement Cornerstoned by Merchant Biotech Fund and Dr Daniel Tillett | ASX:TYP, OTC:TYPTF
Just the Facts: Tryptamine Therapeutics' TRP-8803 Clears Phase 1b Safety Trial | ASX:TYP, OTC:TYPTF
Trending AU Stocks
ASX High Dividend ASX High Dividend